Psychometric Evaluation Of The Psoriasis Symptom Diary Using Phase 3 Trial Data
Strober, B, Zhao, Y, Tran, M.H, Gnanasakthy, A, Nelson, L.M, McLeod, L.D, Mordin, M, Gottlieb, A, Elewski, B, Lebwohl, M.G
Published in Value in health (01.05.2014)
Published in Value in health (01.05.2014)
Get full text
Journal Article
Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks
Reich, K., Warren, R.B., Iversen, L., Puig, L., Pau‐Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S., Lebwohl, M.G., Cantrell, W., Blauvelt, A., Thaçi, D.
Published in British journal of dermatology (1951) (01.03.2020)
Published in British journal of dermatology (1951) (01.03.2020)
Get full text
Journal Article
LB946 Spesolimab controls chronic inflammation in GPP
Krueger, J.G., Gudjonsson, J.E., Morita, A., Lebwohl, M.G., Warren, R.B., Mostaghimi, A., Langley, R., Tang, M., Visvanathan, S., Thoma, C., Strober, B.
Published in Journal of investigative dermatology (01.08.2024)
Published in Journal of investigative dermatology (01.08.2024)
Get full text
Journal Article
Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up
Papp, K.A., Lebwohl, M.G., Puig, L., Ohtsuki, M., Beissert, S., Zeng, J., Rubant, S., Sinvhal, R., Zhao, Y., Soliman, A.M., Alperovich, G., Leonardi, C.
Published in British journal of dermatology (1951) (01.12.2021)
Published in British journal of dermatology (1951) (01.12.2021)
Get full text
Journal Article
605 Long-term management of moderate-to-severe plaque psoriasis: Maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion
Gold, L. F. Stein, Lebwohl, M.G., Bhatia, N., Lin, T., Pillai, R.
Published in Journal of investigative dermatology (01.07.2020)
Published in Journal of investigative dermatology (01.07.2020)
Get full text
Journal Article
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study
Lebwohl, M.G., Gordon, K.B., Gallo, G., Zhang, L., Paul, C.
Published in Journal of the European Academy of Dermatology and Venereology (01.02.2020)
Published in Journal of the European Academy of Dermatology and Venereology (01.02.2020)
Get full text
Journal Article
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3
Papp, K.A., Gordon, K.B., Langley, R.G., Lebwohl, M.G., Gottlieb, A.B., Rastogi, S., Pillai, R., Israel, R.J.
Published in British journal of dermatology (1951) (01.08.2018)
Published in British journal of dermatology (1951) (01.08.2018)
Get full text
Journal Article
Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials
Hsu, S., Green, L.J., Lebwohl, M.G., Wu, J.J., Blauvelt, A., Jacobson, A.A.
Published in British journal of dermatology (1951) (01.04.2020)
Published in British journal of dermatology (1951) (01.04.2020)
Get full text
Journal Article
Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey
van de Kerkhof, P.C.M., Reich, K., Kavanaugh, A., Bachelez, H., Barker, J., Girolomoni, G., Langley, R.G., Paul, C.F., Puig, L., Lebwohl, M.G.
Published in Journal of the European Academy of Dermatology and Venereology (01.10.2015)
Published in Journal of the European Academy of Dermatology and Venereology (01.10.2015)
Get full text
Journal Article
Brodalumab 用于对乌司奴单抗应答不足的患者
Langley, R.G., Armstrongi, A.W., Lebwohl, M.G., Blauvelt, A., Hsu, S., Tyring, S., Rastogi, S., Pillai, R., Israel, R.
Published in British journal of dermatology (1951) (01.02.2019)
Published in British journal of dermatology (1951) (01.02.2019)
Get full text
Journal Article
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials
Langley, R.G., Armstrong, A.W., Lebwohl, M.G., Blauvelt, A., Hsu, S., Tyring, S., Rastogi, S., Pillai, R., Israel, R.
Published in British journal of dermatology (1951) (01.02.2019)
Published in British journal of dermatology (1951) (01.02.2019)
Get full text
Journal Article
Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
Warren, R.B., Carrascosa, J.M., Fumero, E., Schoenenberger, A., Lebwohl, M.G., Szepietowski, J.C., Reich, K.
Published in Journal of the European Academy of Dermatology and Venereology (01.04.2021)
Published in Journal of the European Academy of Dermatology and Venereology (01.04.2021)
Get full text
Journal Article
434 Baseline IL-22 expression in atopic dermatitis patients stratifies therapeutic responses to fezakinumab
Pavel, A., Brunner, P.M., Khattri, S., Malik, K., Fuentes-Duculan, J., Garcet, S., Lebwohl, M.G., Krueger, J.G., Guttman-Yassky, E.
Published in Journal of investigative dermatology (01.05.2018)
Published in Journal of investigative dermatology (01.05.2018)
Get full text
Journal Article
Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study
Lebwohl, M.G., Stein Gold, L., Papp, K., Han, G., Pariser, D.M., Lin, T., Harris, S., Jacobson, A.
Published in Journal of the European Academy of Dermatology and Venereology (01.05.2021)
Published in Journal of the European Academy of Dermatology and Venereology (01.05.2021)
Get full text
Journal Article
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2
Fernandez, A.P., Dauden, E., Gerdes, S., Lebwohl, M.G., Menter, M.A., Leonardi, C.L., Gooderham, M., Gebauer, K., Tada, Y., Lacour, J.P., Bianchi, L., Egeberg, A., Pau‐Charles, I., Mendelsohn, A.M., Rozzo, S.J., Mehta, N.N.
Published in Journal of the European Academy of Dermatology and Venereology (01.10.2022)
Published in Journal of the European Academy of Dermatology and Venereology (01.10.2022)
Get full text
Journal Article
一项在银屑病患者中开展的 tildrakizumab 药物研究
Reich, K., Warren, R.B., Iversen, L., Puig, L., Pau‐Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S., Lebwohl, M.G., Cantrell, W., Blauvelt, A., Thaçi, D.
Published in British journal of dermatology (1951) (01.03.2020)
Published in British journal of dermatology (1951) (01.03.2020)
Get full text
Journal Article
279 Reduced pruritus and signs of atopic dermatitis in phase 3 trials with a nonsteroidal topical phosphodiesterase inhibitor, crisaborole
Hebert, A.A., Eichenfield, L., Lebwohl, M.G., Paller, A.S., Simpson, E.L., Tom, W.L., Zane, L.T.
Published in Journal of investigative dermatology (01.05.2016)
Published in Journal of investigative dermatology (01.05.2016)
Get full text
Journal Article
Chronic lichen sclerosus successfully treated with intralesional adalimumab
Feig, J.L., Gribetz, M.E., Lebwohl, M.G.
Published in British journal of dermatology (1951) (01.03.2016)
Published in British journal of dermatology (1951) (01.03.2016)
Get full text
Journal Article